Inhibitors of MLH1 and/or PMS2 for treatment of cancer

Inhibitors of MLH1 and/or PMS2 for treatment of cancer

The present invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R6 and R10 are each as defined herein, targeting MLH1 and/or PMS2 proteins as components of a DNA mismatch repair (MMR) process. The invention also relates to processes for preparing these compounds, pharmaceutical co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BRAGG JULIAN, ROFFEY JON, DRYSDALE MARTIN, CLARK DAVID, WINSHIP PAUL
Format: Patent
Sprache:chi ; eng
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator BRAGG JULIAN
ROFFEY JON
DRYSDALE MARTIN
CLARK DAVID
WINSHIP PAUL
description The present invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R6 and R10 are each as defined herein, targeting MLH1 and/or PMS2 proteins as components of a DNA mismatch repair (MMR) process. The invention also relates to processes for preparing these compounds, pharmaceutical compositions comprising them, and their use in the treatment of proliferative diseases such as cancer as well as other diseases or conditions involving MLH1 and/or PMS2 activity. 本发明涉及靶向作为DNA错配修复(MMR)过程组分的MLH1和/或PMS2蛋白的式(I)的化合物：其中R1、R2、R3、R4、R6和R10各自如本文所定义。本发明还涉及制备这些化合物的方法，包含它们的药物组合物，以及它们在治疗增殖性疾病如癌症以及涉及MLH1和/或PMS2活性的其他疾病或病况中的用途。
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN115996907A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN115996907A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN115996907A3</originalsourceid><addsrcrecordid>eNrjZDDzzMvITMosyS8qVshPU_D18TBUSMxL0c8vUgjwDTZSSAMySopSE0tyU_NKQCqSE_OSU4t4GFjTEnOKU3mhNDeDoptriLOHbmpBfnxqcUFicmpeakm8s5-hoamlpZmlgbmjMTFqANsuK_4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Inhibitors of MLH1 and/or PMS2 for treatment of cancer</title><source>esp@cenet</source><creator>BRAGG JULIAN ; ROFFEY JON ; DRYSDALE MARTIN ; CLARK DAVID ; WINSHIP PAUL</creator><creatorcontrib>BRAGG JULIAN ; ROFFEY JON ; DRYSDALE MARTIN ; CLARK DAVID ; WINSHIP PAUL</creatorcontrib><description>The present invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R6 and R10 are each as defined herein, targeting MLH1 and/or PMS2 proteins as components of a DNA mismatch repair (MMR) process. The invention also relates to processes for preparing these compounds, pharmaceutical compositions comprising them, and their use in the treatment of proliferative diseases such as cancer as well as other diseases or conditions involving MLH1 and/or PMS2 activity. 本发明涉及靶向作为DNA错配修复(MMR)过程组分的MLH1和/或PMS2蛋白的式(I)的化合物：其中R1、R2、R3、R4、R6和R10各自如本文所定义。本发明还涉及制备这些化合物的方法，包含它们的药物组合物，以及它们在治疗增殖性疾病如癌症以及涉及MLH1和/或PMS2活性的其他疾病或病况中的用途。</description><language>chi ; eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20230421&amp;DB=EPODOC&amp;CC=CN&amp;NR=115996907A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20230421&amp;DB=EPODOC&amp;CC=CN&amp;NR=115996907A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BRAGG JULIAN</creatorcontrib><creatorcontrib>ROFFEY JON</creatorcontrib><creatorcontrib>DRYSDALE MARTIN</creatorcontrib><creatorcontrib>CLARK DAVID</creatorcontrib><creatorcontrib>WINSHIP PAUL</creatorcontrib><title>Inhibitors of MLH1 and/or PMS2 for treatment of cancer</title><description>The present invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R6 and R10 are each as defined herein, targeting MLH1 and/or PMS2 proteins as components of a DNA mismatch repair (MMR) process. The invention also relates to processes for preparing these compounds, pharmaceutical compositions comprising them, and their use in the treatment of proliferative diseases such as cancer as well as other diseases or conditions involving MLH1 and/or PMS2 activity. 本发明涉及靶向作为DNA错配修复(MMR)过程组分的MLH1和/或PMS2蛋白的式(I)的化合物：其中R1、R2、R3、R4、R6和R10各自如本文所定义。本发明还涉及制备这些化合物的方法，包含它们的药物组合物，以及它们在治疗增殖性疾病如癌症以及涉及MLH1和/或PMS2活性的其他疾病或病况中的用途。</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDDzzMvITMosyS8qVshPU_D18TBUSMxL0c8vUgjwDTZSSAMySopSE0tyU_NKQCqSE_OSU4t4GFjTEnOKU3mhNDeDoptriLOHbmpBfnxqcUFicmpeakm8s5-hoamlpZmlgbmjMTFqANsuK_4</recordid><startdate>20230421</startdate><enddate>20230421</enddate><creator>BRAGG JULIAN</creator><creator>ROFFEY JON</creator><creator>DRYSDALE MARTIN</creator><creator>CLARK DAVID</creator><creator>WINSHIP PAUL</creator><scope>EVB</scope></search><sort><creationdate>20230421</creationdate><title>Inhibitors of MLH1 and/or PMS2 for treatment of cancer</title><author>BRAGG JULIAN ; ROFFEY JON ; DRYSDALE MARTIN ; CLARK DAVID ; WINSHIP PAUL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN115996907A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>BRAGG JULIAN</creatorcontrib><creatorcontrib>ROFFEY JON</creatorcontrib><creatorcontrib>DRYSDALE MARTIN</creatorcontrib><creatorcontrib>CLARK DAVID</creatorcontrib><creatorcontrib>WINSHIP PAUL</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BRAGG JULIAN</au><au>ROFFEY JON</au><au>DRYSDALE MARTIN</au><au>CLARK DAVID</au><au>WINSHIP PAUL</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Inhibitors of MLH1 and/or PMS2 for treatment of cancer</title><date>2023-04-21</date><risdate>2023</risdate><abstract>The present invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R6 and R10 are each as defined herein, targeting MLH1 and/or PMS2 proteins as components of a DNA mismatch repair (MMR) process. The invention also relates to processes for preparing these compounds, pharmaceutical compositions comprising them, and their use in the treatment of proliferative diseases such as cancer as well as other diseases or conditions involving MLH1 and/or PMS2 activity. 本发明涉及靶向作为DNA错配修复(MMR)过程组分的MLH1和/或PMS2蛋白的式(I)的化合物：其中R1、R2、R3、R4、R6和R10各自如本文所定义。本发明还涉及制备这些化合物的方法，包含它们的药物组合物，以及它们在治疗增殖性疾病如癌症以及涉及MLH1和/或PMS2活性的其他疾病或病况中的用途。</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language chi ; eng
recordid cdi_epo_espacenet_CN115996907A
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
title Inhibitors of MLH1 and/or PMS2 for treatment of cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T04%3A39%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BRAGG%20JULIAN&rft.date=2023-04-21&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN115996907A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true